DrugPatentWatch Database Preview
COTELLIC Drug Profile
Which patents cover Cotellic, and when can generic versions of Cotellic launch?
Cotellic is a drug marketed by Genentech Inc and is included in one NDA. There are two patents protecting this drug.
This drug has fifty-two patent family members in thirty countries.
The generic ingredient in COTELLIC is cobimetinib fumarate. One supplier is listed for this compound. Additional details are available on the cobimetinib fumarate profile page.
Summary for COTELLIC
| International Patents: | 52 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 51 |
| Clinical Trials: | 12 |
| Patent Applications: | 63 |
| Drug Prices: | Drug price information for COTELLIC |
| Prior Art and Litigation Support | Order Prior Art and Litigation support for COTELLIC |
| DailyMed Link: | COTELLIC at DailyMed |
Generic Entry Opportunity Date for COTELLIC
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for COTELLIC
| Drug Class | Kinase Inhibitor |
| Mechanism of Action | Kinase Inhibitors |
Synonyms for COTELLIC
| (3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)(3-hydroxy-3-((S)-piperidin-2-yl)cyclobutyl)methanone |
| (S)-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)methanone |
| (S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)methanone |
| [3,4-Bis(Fluoranyl)-2-[(2-Fluoranyl-4-Iodanyl-Phenyl)amino]phenyl]-[3-Oxidanyl-3-[(2s)-Piperidin-2-Yl]azetidin-1-Yl]methanone |
| [3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-((s)-3-hydroxy-3-piperidin-2-yl-azetidin-1-yl)-methanone |
| [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]{3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl}methanone |
| [3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone |
| [3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl][3-hydroxy-3-[(2S)-2-piperidinyl]-1-azetidinyl]methanone |
| {3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}{3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl}methanone |
| 1029872-29-4 |
| 1369665-02-0 |
| 3556AH |
| 6EXI96H8SV |
| 934660-93-2 |
| AB0072274 |
| AK173907 |
| AKOS025396263 |
| BC600781 |
| BCP9000716 |
| BDBM50391802 |
| bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate |
| BSMCAPRUBJMWDF-KRWDZBQOSA-N |
| C21H21F3IN3O2 |
| CHEBI:90851 |
| CHEBI:90853 |
| CHEMBL2146883 |
| CHEMBL2364607 |
| Cobimetinib |
| Cobimetinib (GDC-0973, RG7420) |
| Cobimetinib (USAN/INN) |
| Cobimetinib [USAN:INN] |
| Cobimetinib Butyrate |
| Cobimetinib Fumarate |
| Cobimetinib fumarate (USAN) |
| Cobimetinib fumarate [USAN] |
| Cobimetinib hemifumarate |
| cometinib |
| Cotellic (TN) |
| CS-0521 |
| D10405 |
| D10615 |
| DB05239 |
| DTXSID60239435 |
| ER29L26N1X |
| EUI |
| EX-A673 |
| FT-0675878 |
| GDC 0973 |
| GDC-0973 |
| GDC-0973 hemifumarate |
| GDC0973 |
| GDC0973; XL518; Cobimetinib |
| GTPL7626 |
| HY-13064 |
| J-525162 |
| KB-77527 |
| KS-0000059E |
| Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-((2S)-2-piperidinyl)-1-azetidinyl)- |
| Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1) |
| MolPort-028-720-358 |
| NCGC00346455-03 |
| QCR-87 |
| RG 7420 |
| RG-7421 |
| RG7420 |
| s8041 |
| SCHEMBL189565 |
| UNII-6EXI96H8SV |
| UNII-ER29L26N1X |
| W-5863 |
| XL 518 |
| Xl-518 |
| Xl-518 hemifumarate |
| XL518 |
| ZINC60325170 |
US Patents and Regulatory Information for COTELLIC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | COTELLIC | cobimetinib fumarate | TABLET;ORAL | 206192-001 | Nov 10, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Genentech Inc | COTELLIC | cobimetinib fumarate | TABLET;ORAL | 206192-001 | Nov 10, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Genentech Inc | COTELLIC | cobimetinib fumarate | TABLET;ORAL | 206192-001 | Nov 10, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for COTELLIC
Supplementary Protection Certificates for COTELLIC
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1934174 | C01934174/01 | Switzerland | ➤ Sign Up | PRODUCT NAME: COBIMETINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65620 24.08.2015 |
| 1934174 | 122016000033 | Germany | ➤ Sign Up | PRODUCT NAME: COBIMETINIB, OPTIONAL ALS PHARMAZEUTISCH ZULAESSIGES SALZ ODER SOLVAT DAVON, INSBESONDERE COBIMETINIB-HEMIFUMARAT; REGISTRATION NO/DATE: EU/1/15/1048 20151120 |
| 1934174 | CA 2016 00021 | Denmark | ➤ Sign Up | PRODUCT NAME: COBIMETINIB, EVENTUELT I EN HVILKEN SOM HELST FORM BESKYTTET AF GRUNDPATENTET, DER INDBEFATTER FARMACEUTISK ACCEPTABLE SALTE OG SOLVATER, SAERLIGT COBIMETINIB HEMIFUMARAT; REG. NO/DATE: EU/1/15/1048 20151124 |
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
